The Effects of Hydrogen Gas Inhalation on Adverse Left Ventricular Remodeling After Percutaneous Coronary Intervention for ST-Elevated Myocardial Infarction　― First Pilot Study in Humans ―

Yoshinori Katsumata; Fumiya Sano; Takayuki Abe; Tomoyoshi Tamura; Taishi Fujisawa; Yasuyuki Shiraishi; Shun Kohsaka; Ikuko Ueda; Koichiro Homma; Masaru Suzuki; Shigeo Okuda; Yuichiro Maekawa; Eiji Kobayashi; Shingo Hori; Junichi Sasaki; Keiichi Fukuda; Motoaki Sano

doi:10.1253/circj.CJ-17-0105

Late Breaking Clinical Trials (JCS 2017)

The Effects of Hydrogen Gas Inhalation on Adverse Left Ventricular Remodeling After Percutaneous Coronary Intervention for ST-Elevated Myocardial Infarction　― First Pilot Study in Humans ―

Yoshinori Katsumata, Fumiya Sano, Takayuki Abe, Tomoyoshi Tamura, Taishi Fujisawa, Yasuyuki Shiraishi, Shun Kohsaka, Ikuko Ueda, Koichiro Homma, Masaru Suzuki, Shigeo Okuda, Yuichiro Maekawa, Eiji Kobayashi, Shingo Hori, Junichi Sasaki, Keiichi Fukuda, Motoaki Sano

Author information

Yoshinori Katsumata
Department of Cardiology, Keio University School of Medicine
Center for Molecular Hydrogen Medicine, Keio University School of Medicine
Fumiya Sano
Clinical and Translational Research Center, Keio University Hospital
Takayuki Abe
Clinical and Translational Research Center, Keio University Hospital
Tomoyoshi Tamura
Department of Emergency and Critical Care Medicine, Keio University School of Medicine
Center for Molecular Hydrogen Medicine, Keio University School of Medicine
Taishi Fujisawa
Department of Cardiology, Keio University School of Medicine
Yasuyuki Shiraishi
Department of Cardiology, Keio University School of Medicine
Shun Kohsaka
Department of Cardiology, Keio University School of Medicine
Ikuko Ueda
Department of Cardiology, Keio University School of Medicine
Koichiro Homma
Department of Emergency and Critical Care Medicine, Keio University School of Medicine
Center for Molecular Hydrogen Medicine, Keio University School of Medicine
Masaru Suzuki
Department of Emergency and Critical Care Medicine, Keio University School of Medicine
Center for Molecular Hydrogen Medicine, Keio University School of Medicine
Shigeo Okuda
Department of Radiology, Keio University School of Medicine
Yuichiro Maekawa
Department of Cardiology, Keio University School of Medicine
Eiji Kobayashi
Department of Organ Fabrication, Keio University School of Medicine
Center for Molecular Hydrogen Medicine, Keio University School of Medicine
Shingo Hori
Department of Emergency and Critical Care Medicine, Keio University School of Medicine
Junichi Sasaki
Department of Emergency and Critical Care Medicine, Keio University School of Medicine
Keiichi Fukuda
Department of Cardiology, Keio University School of Medicine
Motoaki Sano
Department of Cardiology, Keio University School of Medicine
Center for Molecular Hydrogen Medicine, Keio University School of Medicine

Keywords: Cardiac magnetic resonance imaging, Hydrogen gas, Left ventricular remodeling, Myocardial infarction

JOURNAL FREE ACCESS FULL-TEXT HTML
Supplementary material

2017 Volume 81 Issue 7 Pages 940-947

DOI https://doi.org/10.1253/circj.CJ-17-0105

Editorial (81-7 pp. 936-937)

Browse “Advance online publication” version

Details

Abstract

Background:Hydrogen gas inhalation (HI) reduced infarct size and mitigated adverse left ventricular (LV) remodeling in a rat model of acute myocardial infarction (AMI). We designed a prospective, open-label, rater-blinded clinical pilot study in patients experiencing ST-elevated MI (STEMI).

Methods and Results:The 20 patients with an initial diagnosis of STEMI were assigned to either an HI group (1.3% H₂with 26% oxygen) or a control group (26% oxygen). There were no HI-related severe adverse events. In the full analysis set, the cardiac salvage index as evaluated using cardiac magnetic resonance imaging at 7 days after primary percutaneous coronary intervention (PCI), showed no significant between-group difference (HI: 50.0±24.3%; control: 60.1±20.1%; P=0.43). However, the improvement from day 7 in the HI group was numerically greater than that in the control group in some of the surrogate outcomes at 6-month follow-up, including the LV stroke volume index (HI: 9.2±7.1 mL/m²; control: −1.4±7.2 mL/m²; P=0.03) and the LV ejection fraction (HI: 11.0%±9.3%; control: 1.7%±8.3%; P=0.11).

Conclusions:The first clinical study has shown that HI during PCI is feasible and safe and may also promote LV reverse remodeling at 6 months after STEMI. The study was not powered to test efficacy and a further large-scale trial is warranted. (Clinical trials registration: UMIN00006825)

Corresponding author

Register with J-STAGE for free!